Bruce Power announces milestone in medical Lu-177 production

June 24, 2022, 12:01PMNuclear News
The new IPS installed in Bruce Power’s Unit 7 will produce Lu-177 for treating cancer. (Photo: Bruce Power)

An international collaboration between Bruce Power, Isogen (a joint venture of Kinectrics and Framatome), and ITM Isotope Technologies Munich SE, announced a milestone marking the first time that lutetium-177, a short-lived medical radioisotope, has been produced in a commercial nuclear power reactor.

To continue reading, log in or create a free account!

Related Articles

BWXT announces nuclear manufacturing plant expansion

Investment banking on higher demand for SMR and large nuclear reactors

April 19, 2024, 9:30AMNuclear News

BWX Technologies announced today plans to expand and add advanced manufacturing equipment to its manufacturing plant in Cambridge, Ontario, Canada.A $36.3 million USD ($50M CAD) expansion will...

Framatome signs contracts with Sizewell C

April 18, 2024, 3:02PMNuclear News

French nuclear developer Framatome is slated to deliver key equipment for Sizewell C Ltd.’s two large reactors planned for the United Kingdom’s Suffolk coast.The agreement, reportedly...